SCHEMBL2990983

SCHEMBL2990983

O=C1c2ccccc2C(=O)N1CCc1c[nH]c(=O)[nH]c1=O

nearest known ligand 0.66

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.61
MEN1 O00255 3/20 0.61
KMT2A Q03164 3/20 0.61
GAA P10253 2/20 0.61
NPC1 O15118 2/20 0.61
RAB9A P51151 2/20 0.61
TDP1 Q9NUW8 2/20 0.51
LMNA P02545 3/20 0.49
ALDH1A1 P00352 1/20 0.49
HPGD P15428 1/20 0.49
NPSR1 Q6W5P4 1/20 0.49
RXFP1 Q9HBX9 1/20 0.49
TSHR P16473 1/20 0.48
CASP3 P42574 1/20 0.45
HTT P42858 1/20 0.45
TP53 P04637 1/20 0.45
HSD17B10 Q99714 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL735125 0.76 MAPT (1.00) MAPTMEN1KMT2AGAANPC1
SCHEMBL5635894 0.75 MAPT (0.53) MAPTMEN1KMT2AGAANPC1
SCHEMBL9339801 0.75 MAPT (0.56) MAPTMEN1KMT2AGAANPC1
SCHEMBL4353311 0.74 DPYD (0.50) MAPTGAALMNAALDH1A1TSHR
SCHEMBL600199 0.72 NPSR1 (0.55) MAPTMEN1KMT2AGAANPC1
SCHEMBL2534548 0.71 MAPT (0.65) MAPTMEN1KMT2AGAANPC1
SCHEMBL5635893 0.71 MAPT (0.51) MAPTMEN1KMT2AGAANPC1
SCHEMBL6699936 0.70 GLS (0.71) MAPTNPC1RAB9ATDP1CASP3
SCHEMBL2535334 0.70 GAA (0.73) MAPTMEN1KMT2AGAANPC1
SCHEMBL650217 0.70 MAPT (0.86) MAPTMEN1KMT2AGAANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7777024-B2 Process for preparing a pentopyranosyl nucleic acid conjugate AVENTIS RESEARCH & TECHNOLOGIES GMBH & CO. (DE) 2010-08-17 US disclosed
US-20090221793-A1 PROCESS FOR PREPARING A PENTOPYRANOSYL NUCLEIC ACID CONJUGATE SANOFI-AVENTIS S.A. (FR) 2009-09-03 US disclosed
US-7501506-B2 Pentopyranosyl nucleic acid conjugates NANOGEN RECOGNOMICS GMBH (DE) 2009-03-10 US disclosed
US-7153955-B2 Pentopyranosyl nucleic acid arrays, and uses thereof NANOGEN RECOGNOMICS GMBH (DE) 2006-12-26 US disclosed
US-20060270840-A1 Pentopyranosyl nucleic acid conjugates SANOFI-AVENTIS S.A. (FR) 2006-11-30 US disclosed
EP-1034180-B1 LINKER NUCLEOSIDE, AND PRODUCTION AND USE OF THE SAME NANOGEN RECOGNOMICS GMBH (DE) 2006-03-29 EP disclosed
US-20050053945-A1 Process for the preparation of a pentopyranosyl conjugate NANOGEN RECOGNOMICS GMBH 2005-03-10 US disclosed
US-20050004356-A1 Linker nucleoside, its preparation and use NANOGEN RECOGNOMICS GMBH (DE) 2005-01-06 US disclosed
US-20040198966-A1 Pentopyranosylnucleoside, its preparation and use NANOGEN RECOGNOMICS GMBH 2004-10-07 US disclosed
EP-1017703-B1 PENTOPYRANOSYL NUCLEOSIDE, AND PRODUCTION AND USE OF THE SAME NANOGEN RECOGNOMICS GMBH (DE) 2004-04-28 EP disclosed
US-6608186-B1 Of given formula; use for the production of a therapeutic, diagnostic and/or electronic component; use in the construction of supramolecular units NANOGEN RECOGNOMICS GMBH (DE) 2003-08-19 US disclosed
US-20030039997-A1 Pentopyranosyl nucleic acid arrays, and uses thereof AVENTIS RESEARCH AND TECHNOLOGIES GMBH & CO. KG (DE) 2003-02-27 US disclosed
EP-1019423-B1 METHOD FOR PRODUCING A PENTOPYRANOSYL NUCLEOSIDE NANOGEN RECOGNOMICS GMBH (DE) 2003-02-26 EP disclosed
US-6506896-B1 Conjugated to peptides, proteins, nucleic acids, antibodies, RNA, or DNA; medical diagnosis, electronics NANOGEN RECOGNOMICS GMBH (DE) 2003-01-14 US disclosed
EP-1034180-A2 LINKER NUCLEOSIDE, AND PRODUCTION AND USE OF THE SAME Nanogen Recognomics GmbH (DE) 2000-09-13 EP disclosed
EP-1019423-A2 METHOD FOR PRODUCING A PENTOPYRANOSYL NUCLEOSIDE Nanogen Recognomics GmbH (DE) 2000-07-19 EP disclosed
EP-1017703-A2 PENTOPYRANOSYL NUCLEOSIDE, AND PRODUCTION AND USE OF THE SAME Nanogen Recognomics GmbH (DE) 2000-07-12 EP disclosed
WO-1999015540-A2 METHOD FOR PRODUCING A PENTOPYRANOSYL NUCLEOSIDE AVENTIS RESEARCH & TECHNOLOGIES GMBH & CO KG (DE) 1999-04-01 WO disclosed
WO-1999015542-A2 LINKER NUCLEOSIDE, AND PRODUCTION AND USE OF THE SAME AVENTIS RESEARCH & TECHNOLOGIES GMBH & CO. KG (DE) 1999-04-01 WO disclosed
WO-1999015539-A2 PENTOPYRANOSYL NUCLEOSIDE, AND PRODUCTION AND USE OF THE SAME AVENTIS RESEARCH & TECHNOLOGIES GMBH & CO. KG (DE) 1999-04-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090221793-A1 PROCESS FOR PREPARING A PENTOPYRANOSYL NUCLEIC ACID CONJUGATE RNGTT, NT5C3B, FUT6 MAPT 4293/4885MEN1 2365/4885KMT2A 2433/4885
US-20040198966-A1 Pentopyranosylnucleoside, its preparation and use FUT6, ST3GAL3, FUT5 MAPT 2753/4885MEN1 891/4885KMT2A 4304/4885
US-20050004356-A1 Linker nucleoside, its preparation and use RNGTT, NSUN2, NSUN3 MAPT 2837/4885MEN1 3656/4885KMT2A 2254/4885
US-20050053945-A1 Process for the preparation of a pentopyranosyl conjugate FUT6, FUT5, FUCA2 MAPT 2338/4885MEN1 874/4885KMT2A 3591/4885
US-20060270840-A1 Pentopyranosyl nucleic acid conjugates FUT6, RNGTT, B3GAT3 MAPT 4091/4885MEN1 3055/4885KMT2A 2501/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.